Palmetto Isotopes, LLC, Ridgeland, SC
Is Palmetto Isotopes, LLC registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location.
Does Palmetto Isotopes, LLC hold a South Carolina pharmacy license?
State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.
Has Palmetto Isotopes, LLC had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Feb 28, 2025) for Palmetto Isotopes, LLC. State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Palmetto Isotopes, LLC
- Location
- Ridgeland, SC
- Type as FDA labels it
- Not stated
- FDA’s note
- Nuclear Phamacy
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Feb 28, 2025
- FDA Data Dashboard inspections
- 1 inspection: 1 OAI; 1 published Form 483
- Form 483 text on this page
- 1 Form 483, 6 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Palmetto Isotopes, LLC, with 1 dated action.
| Document | |||
|---|---|---|---|
| Feb 28, 2025 | Form 483 | 483 Issued 02/28/2025 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists PALMETTO ISOTOPES, LLC, Ridgeland, SC (FEI number 3016492204), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Feb 28, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3016492204 | 1263852 |
Form 483s FDA has published for this site
- Feb 28, 2025: Form 483 to PALMETTO ISOTOPES, LLC, published Mar 28, 2025. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Feb 19, 2025 to Feb 28, 2025: 6 observations
- Firm on the cover
- PALMETTO ISOTOPES, LLC, 95 Bees Creek Rd, Ridgeland, SC 29936-7540
- FEI number
- 3016492204
- Establishment type on the cover
- Nuclear Pharmacy
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Inadequate routine environmental monitoring in the ISO 5 area.
Specifically,
Environmental monitoring (EM) of the nuclear lab (Compounding Room '<"J , used for processing radiopharmaceuticals intended to be sterile is inadequate. Air sampling for EM in the ISO 7 buffer room is conducted <Redacted B4> by a third-party company; however, viable air monitoring has never been conducted in the ISO 5 .Primary Engineering Controls (PECs). There are <Redacted B4> ISO 5 PECs in Compounding Room <Redacted B4> (Equipment IDs: <Redacted B4>. Your firm produces approximately <Redacted B4> syringes of radiopharmaceuticals per day on average.
Observation 2
Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.
Specifically,
The media fill conducted for the Compounding RoomO is inadequate, described as follows:
A. The media fill process does not simulate the production of sterile radiophaimaceuticals. Your firm conducted a media fill every <Redacted B4> using a <Redacted B4> to withdraw non-sterile media into <Redacted B4> vials as control and into <Redacted B4> vials with a <Redacted B4>. however, the operators produce approximately <Redacted B4> syringes of radiopharmaceutical products per day on average during the <Redacted B4>. This media fill process simulates the production of vial products; However, it does not consider the production of radiopharmaceutical products in syringes with significantly higher production volumes. For example on 2/24/2025, your firm produced[Jbatches of radiopharmaceuticals products with a total of <Redacted B4> syringes by <Redacted B4> operators in the <Redacted B4> ISO 5 PECs (EquipmentIDs: <Redacted B4> during the <Redacted B4>
B. ...
Observation 3
Smoke studies were not performed under dynamic conditions.
Specifically,
Your firm has no documented evidence demonstrating that the smoke study in the <Redacted B4> ISO 5 PECs in Compounding Room <Redacted B4> was conducted under dynamic conditions. The smoke study is performed <Redacted B4> by a third-party company. For example, the most recent smoke study, performed on 12/24/2024, demonstrated that the system complies with unidirectional airflow requirements as specified in the Unidirectional Airflow Test Protocol; however, no information, records, or videos demonstrating the smoke study was conducted under dynamic conditions were available for review. The only videos available for review were for the smoke study performed in 2020, showing that the smoke study was conducted under static conditions and no unidirectional airflow was demonstrated.
Observation 4
Production areas have difficult to clean or contain porous, particle generating, or visibly duty equipment or surfaces.
Specifically,
On 2/19/2025, during the walkthrough of Compounding Room <Redacted B4> it was observed:
• The grid of the HEP A filter appeared duty and discolored inside the ISO 5 PEC, Equipment ID: <Redacted B4>
• There were hard-to-clean items inside the ISO 5 PEC, Equipment ID: <Redacted B4> including twisted charging cables connected to string lights and scanners.
Your firm uses this ISO 5 PEC to fill syringes with radiopharmaceuticals intended to be sterile, as well as for the radioactivity testing of radiolabeled white blood cells.
Observation 5
Personnel engaged in aseptic processing were observed wearing non-sterile gloves.
Specifically,
During the production of MAA Tc99m (LEU), Lot# K-20250220-009 on 2/20/2025 and Sestamibi Tc99m, Lot# K-20250225-010 on 2/25/2025, both intended to be sterile it was observed the operator wore non-sterile gloves for aseptic processing, including adding <Redacted B4> to the cold kits, drawing solutions from vials containing sterile saline or tagged cold kits, and capping the syringes. These two lots have been distributed to the firm's customers.
Observation 6
Use of a sporicidal agent in the facility's classified areas was improper.
Specifically,
A sporicidal agent is not used in the disinfection of any return dose container (pigs). According to the procedure for Cleaning and Disinfecting Lead Unit Dose Shields (PIGS), the exterior of the pigs is initially wiped thoroughly with the appropriate solution. The initial surface of the pigs is then sprayed with sterile <Redacted B4> however, a sporicidal agent has never been used to disinfect the pigs. Additionally, the interior surfaces of the pigs have never been wiped with any disinfectant. The pigs are used in ISO 5 PECs to hold finished syringes during the aseptic processing of radiopharmaceuticals.
State board of pharmacy records
State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.